Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ayse Salihoglu

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Leukemia & Lymphoma|July 3, 2018
Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitorsYucel Erbilgin, Ahmet Emre Eskazan, Ozden Hatirnaz Ng, et al.
British Journal of Haematology|May 13, 2014
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylateAhmet Emre Eskazan, Mesut Ayer, Bulent Kantarcioglu, et al.
African Health Sciences|March 13, 2023
Cytogenetic profile of adult AML patients in Turkey: a single center study with comprehensive comparison with literatureAyse Cirakoglu, Rahiye Dilhan Kuru, Sukriye Yilmaz, et al.
Hematology (Amsterdam, Netherlands)|October 10, 2017
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literatureSeniz Ongoren, Ahmet Emre Eskazan, Veysel Suzan, et al.
Journal of Clinical Pathology|January 27, 2016
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemiaEda Tanrikulu Simsek, Ahmet Emre Eskazan, Mahir Cengiz, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 30, 2017
Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and GlivecAhmet Emre Eskazan, Sevil Sadri, Dilek Keskin, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Leukemia & Lymphoma|July 3, 2018
Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitorsYucel Erbilgin, Ahmet Emre Eskazan, Ozden Hatirnaz Ng, et al.
British Journal of Haematology|May 13, 2014
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylateAhmet Emre Eskazan, Mesut Ayer, Bulent Kantarcioglu, et al.
African Health Sciences|March 13, 2023
Cytogenetic profile of adult AML patients in Turkey: a single center study with comprehensive comparison with literatureAyse Cirakoglu, Rahiye Dilhan Kuru, Sukriye Yilmaz, et al.
Hematology (Amsterdam, Netherlands)|October 10, 2017
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literatureSeniz Ongoren, Ahmet Emre Eskazan, Veysel Suzan, et al.
Journal of Clinical Pathology|January 27, 2016
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemiaEda Tanrikulu Simsek, Ahmet Emre Eskazan, Mahir Cengiz, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 30, 2017
Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and GlivecAhmet Emre Eskazan, Sevil Sadri, Dilek Keskin, et al.
Pageof 4